
    
      A single arm, prospective, multicenter, non-randomized and open registry up to 1 Year
      Follow-up with the Symetis ACURATE TAâ„¢ which is an aortic bioprosthesis for minimal invasive
      implantation via transapical access to treat patients with severe symptomatic aortic stenosis
      where surgical aortic valve replacement (SAVR) via open surgery is considered to be
      associated with high surgical risk for evaluating the safety and performance of the
      implantation and the safety at 30-Day Follow-up.
    
  